Celldex Therapeutics Inc (CLDX)

Nov 23, 2024

Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright - Defense World

Nov 23, 2024

Nov 22, 2024

What is HC Wainwright's Forecast for CLDX FY2025 Earnings? - MarketBeat

Nov 22, 2024

Nov 22, 2024

Jennison Associates LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Nov 22, 2024

Nov 20, 2024

Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St

Nov 20, 2024

Nov 20, 2024

Celldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 20, 2024

Nov 20, 2024

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times

Nov 20, 2024

Nov 20, 2024

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga

Nov 20, 2024

Nov 19, 2024

Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks

Nov 19, 2024

Nov 16, 2024

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat

Nov 16, 2024

Nov 15, 2024

Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada

Nov 15, 2024

Nov 15, 2024

Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India

Nov 14, 2024

Nov 13, 2024

Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World

Nov 13, 2024

Nov 12, 2024

Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat

Nov 12, 2024

Nov 12, 2024

Celldex Therapeutics CEO Anthony Marucci buys $308,430 in stock By Investing.com - Investing.com UK

Nov 12, 2024

Nov 11, 2024

Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 11, 2024

Nov 11, 2024

Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan

Nov 11, 2024

Nov 11, 2024

Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat

Nov 11, 2024

Nov 11, 2024

What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat

Nov 11, 2024

Nov 11, 2024

HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World

Nov 11, 2024

Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat

Nov 08, 2024

Nov 08, 2024

Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 08, 2024

Nov 08, 2024

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 08, 2024

Nov 06, 2024

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 06, 2024

Nov 06, 2024

Celldex: Q3 Earnings Snapshot - San Antonio Express-News

Nov 06, 2024

Nov 06, 2024

Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 06, 2024

Nov 06, 2024

Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Nov 05, 2024

Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa

Nov 05, 2024

Nov 05, 2024

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat

Nov 05, 2024

Nov 05, 2024

Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India

Nov 05, 2024

Nov 04, 2024

Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha

Nov 04, 2024

Nov 04, 2024

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire

Nov 04, 2024

Nov 04, 2024

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat

Nov 03, 2024

Oct 31, 2024

Evommune raises $115M to accelerate immune drug tests - Yahoo Finance

Oct 31, 2024

Oct 29, 2024

Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury

Oct 29, 2024

Oct 29, 2024

Celldex Therapeutics (NASDAQ:CLDX) Trading Down 6%What's Next? - MarketBeat

Oct 29, 2024

Oct 29, 2024

Prurigo Nodularis Pipeline Update 2024: FDA Approvals, - openPR

Oct 29, 2024

Oct 29, 2024

Celldex shares hold as analyst maintains Buy rating By Investing.com - Investing.com UK

Oct 29, 2024

Oct 29, 2024

Celldex selloff creates buying opportunity, says Guggenheim - Yahoo Finance

Oct 29, 2024

Oct 28, 2024

Celldex shares gain as TD Cowen affirms Buy rating on robust Ph2 data - Investing.com UK

Oct 28, 2024

Oct 28, 2024

Analyst Expectations For Celldex Therapeutics's Future - Benzinga

Oct 28, 2024

Oct 28, 2024

HC Wainwright Reaffirms "Buy" Rating for Celldex Therapeutics (NASDAQ:CLDX) - MarketBeat

Oct 28, 2024

Oct 28, 2024

Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India

Oct 28, 2024

Oct 28, 2024

Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years - Yahoo Finance

Oct 28, 2024